BeOne Medicines Ltd

49BA

Company Profile

  • Business description

    BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

  • Contact

    c/o BeOne Medicines I GmbH
    94 Aeschengraben 27
    21st Floor
    Basel4051
    CHE

    T: +41 616851900

    E: [email protected]

    https://www.beonemedicines.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    12,000

Stocks News & Analysis

stocks

3 ASX opportunities after earnings season

Uncovering key opportunities following February’s results.
stocks

Oracle earnings: Solid execution secures revenue target and mitigates investor concerns

We raise our fair value estimate for Oracle stock.
stocks

US dividend shares are getting a boost from the HALO trade. Can it last?

Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.1031.300.36%
CAC 407,911.53145.83-1.81%
DAX 4023,447.29142.36-0.60%
Dow JONES (US)46,558.47119.38-0.26%
FTSE 10010,261.1544.00-0.43%
HKSE25,465.60251.16-0.98%
NASDAQ22,105.36206.62-0.93%
Nikkei 22553,779.8639.75-0.07%
NZX 50 Index13,154.7232.62-0.25%
S&P 5006,632.1940.43-0.61%
S&P/ASX 2008,613.3037.700.44%
SSE Composite Index4,095.450.000.00%

Market Movers